CD80 and neoplasm: Regression of CD80+ tumors following this immunotherapy regimen was abrogated in IFNγ deficient mice, and 50% of mice who had complete regression of CD80+ tumors rejected tumor transplantation upon re-challenge, firmly establishing an immune mechanism.